Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• Recurrent hemolytic uremic syndrome (recHUS) is a complex disorder with poorly understood pathogenesis.
• A significant portion of recHUS patients (30-50%) exhibit abnormalities in complement factor H or membrane-bound inhibitors, leading to complement activation.
• recHUS carries a high risk of end-stage renal disease and other severe complications.

Purpose of the Study:

• To investigate the role of complement activation in recHUS by measuring terminal complement complex (TCC) levels.
• To compare TCC levels in recHUS patients with healthy individuals.
• To explore the relationship between TCC levels, C3 levels, and disease outcomes in recHUS.

Main Methods:

• Evaluated 42 recHUS patients from five European countries.
• Measured TCC in plasma, serum, and zymosan-activated serum (Z-serum) using an enzyme-linked immunosorbent assay.
• Compared TCC levels to those of 16 healthy controls.

Main Results:

• recHUS patients exhibited significantly higher TCC levels in plasma and serum compared to controls.
• Patients with low C3 levels showed even higher plasma and serum TCC levels.
• The ratio of Z-serum to serum TCC was significantly lower in recHUS patients, indicating increased complement consumption.

Conclusions:

• Elevated TCC levels in recHUS suggest heightened complement activation and consumption.
• TCC may contribute to cell toxicity and the poor prognosis observed in recHUS.
• Therapeutic strategies targeting TCC formation, such as factor H substitution, warrant further investigation.